Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep
- PMID: 22339174
- PMCID: PMC3402814
- DOI: 10.1111/j.1476-5381.2012.01904.x
Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep
Abstract
BACKGROUND AND PURPOSE The urocortin (Ucn) peptides are emerging as potential therapeutic targets for heart disease. However, pharmacokinetic (PK) and pharmacodynamic (PD) data are lacking. Therefore, we investigated the PK/PD for all three Ucns. EXPERIMENTAL APPROACH Seven sheep received 1 µg·kg(-1) boluses of Ucn1, Ucn2 and Ucn3. Population PK/PD models were developed to describe the time course of the haemodynamic effects. RESULTS The population estimate for Ucn1 clearance (0.486 L·h(-1)) was lower than that for Ucn2 (21.7 L·h(-1)) and Ucn3 (220 L·h(-1)), while steady-state volumes of distribution were similar for Ucn1 and Ucn2 (∼8 L) but substantially larger for Ucn3 (23.5 L). Ucn1 disposition was adequately described by a two-compartment model, with a one-compartment model required for Ucn2 and Ucn3. The half-life for Ucn1 was 2.9 h (α phase) and 8.3 h (β phase), and 15.7 and 4.4 min for Ucn2 and Ucn3 respectively. All Ucns produced significant increases in heart rate, cardiac output and left ventricular systolic and mean arterial pressures, and decreases in left atrial pressure and peripheral resistance. Delayed-effect pharmacodynamic models best described the time course of haemodynamic responses, with effects more rapid and less prolonged for Ucn2 and Ucn3 than Ucn1. Similar and physiologically plausible estimated baseline (E(0)) effects were exhibited by all Ucns, whereas EC(50) values were generally greater for Ucn1. CONCLUSIONS AND IMPLICATIONS Relative to Ucn1, both the PK and haemodynamic responses to Ucn2 and Ucn3 occurred more rapidly. Our data provide important comparative information, useful to the rational design of future clinical studies.
© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.
Figures



Similar articles
-
The effects of CRF and the urocortins on the hippocampal acetylcholine release in rats.Neuropeptides. 2021 Aug;88:102147. doi: 10.1016/j.npep.2021.102147. Epub 2021 Apr 20. Neuropeptides. 2021. PMID: 33932861
-
Urocortin 3 inhibits cardiac sympathetic nerve activity in conscious sheep.J Cardiovasc Pharmacol. 2011 Oct;58(4):418-23. doi: 10.1097/FJC.0b013e31822707a4. J Cardiovasc Pharmacol. 2011. PMID: 21697721
-
Mechanisms of cardiovascular actions of urocortins in the hypothalamic arcuate nucleus of the rat.Am J Physiol Heart Circ Physiol. 2013 Jul 15;305(2):H182-91. doi: 10.1152/ajpheart.00138.2013. Epub 2013 May 17. Am J Physiol Heart Circ Physiol. 2013. PMID: 23686711 Free PMC article.
-
Urocortins: Actions in health and heart failure.Clin Chim Acta. 2017 Nov;474:76-87. doi: 10.1016/j.cca.2017.09.003. Epub 2017 Sep 6. Clin Chim Acta. 2017. PMID: 28887029 Review.
-
The role of urocortins in the cardiovascular system.J Physiol Pharmacol. 2014 Dec;65(6):753-66. J Physiol Pharmacol. 2014. PMID: 25554979 Review.
Cited by
-
Urocortin 3 Gene Transfer Increases Function of the Failing Murine Heart.Hum Gene Ther. 2019 Jan;30(1):10-20. doi: 10.1089/hum.2018.103. Epub 2018 Oct 2. Hum Gene Ther. 2019. PMID: 30003813 Free PMC article.
-
Agonist bias and agonist-dependent antagonism at corticotrophin releasing factor receptors.Pharmacol Res Perspect. 2020 Jun;8(3):e00595. doi: 10.1002/prp2.595. Pharmacol Res Perspect. 2020. PMID: 32529807 Free PMC article.
-
Intravenous injection of urocortin 1 induces a CRF2 mediated increase in circulating ghrelin and glucose levels through distinct mechanisms in rats.Peptides. 2013 Jan;39:164-70. doi: 10.1016/j.peptides.2012.11.009. Epub 2012 Nov 23. Peptides. 2013. PMID: 23183626 Free PMC article.
-
UCN2: a new candidate influencing pancreatic β-cell adaptations in pregnancy.J Endocrinol. 2020 May;245(2):247-257. doi: 10.1530/JOE-19-0568. J Endocrinol. 2020. PMID: 32106091 Free PMC article.
-
Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection.Mol Cell Biochem. 2015 Jan;398(1-2):135-46. doi: 10.1007/s11010-014-2213-1. Epub 2014 Sep 23. Mol Cell Biochem. 2015. PMID: 25245818
References
-
- Al-Sallami HS, Pavan Kumar VV, Landersdorfer CB, Bulitta JB, Duffull SB. The time course of drug effects. Pharm Stat. 2009;8:176–185. - PubMed
-
- Boeckmann AJ, Sheiner LB, Beal S. NONMEM Users Guide – Part V: Introductory Guide. San Francisco: NONMEM Project Group, University of California at San Franciso; 1994.
-
- Boonprasert P, Lailerd N, Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol. 2008;127:307–312. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources